(Finance) – Positive session for Register, which increases by 3.13%. after yesterday announcing the signing of an agreement with the British pharmaceutical giant GSK, for the exclusive marketing of two urological drugs in 21 EU countries. The Italian company will make an upfront payment of 245 million euros and expects the transaction to bring full benefits from 2024.
The comparison of the title with the FTSEMIBon a weekly basis, shows the greatest relative strength of the pharmaceutical group compared to the index, highlighting the concrete attractiveness of the stock by buyers.
The current scenario of Register shows a loosening of the trendline at the test of the 43.88 Euro support. In the presence of positive elements, the tendency is for an upward evolution of the curve up to testing the 44.94 level. The technical implications favor a continuation of the bearish phase towards new bottoms seen at 43.24.